Virginia Alonso-Espinaco, Miriam Cuatrecasas, Vicente Alonso, Pilar Escudero, Maribel Marmol, Carlos Horndler, Javier Ortego, Rosa Gallego, Jordi Codony-Servat, Xabier Garcia-Albeniz, Pedro Jares, Antoni Castells, Juan José Lozano, Rafael Rosell, Joan Maurel
INTRODUCTION: Chemotherapy is the principal treatment in metastatic colorectal cancer (mCRC) patients. RAC1b, a RAC1 spliced variant, is over-expressed in colorectal cancer (CRC), and impairs apoptosis by activation of nuclear-factor-KB. Since RAC1b has been associated with the BRAF(V600E) mutation, associated with poor prognosis in CRC, we evaluated the role of RAC1b expression as a predictor of chemotherapy efficacy in mCRC. METHODS: We analysed KRAS and BRAF mutation, microsatellite instability and RAC1b expression in 157 mCRC patients treated with FOLFOX/XELOX in first-line therapy...
July 2014: European Journal of Cancer